Adrenalectomy prevents renal ischemia-reperfusion injury

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 4, 2009, Pages

  Ramírez, Victoria ^a,b   Trujillo, Joyce ^a,b   Valdes, Rafael ^a,b   Uribe, Norma ^b   Cruz, Cristino ^b   Gamba, Gerardo ^a,b   Bobadilla, Norma A ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Endothelin; Mineralocorticoid receptor; Oxidative stress; Rho kinase

Indexed keywords

ALDOSTERONE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RHO KINASE;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GLOMERULUS FILTRATION RATE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY;

EID: 70349633480     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00252.2009     Document Type: Article

References (61)

1. Aebi HE. Catalase. In: Methods of Enzymatic Analysis, edited by Bergmeyer HU. Weinheim, Germany: Verlag Chemie, 1982, p. 273-286.
2. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, Takeuchi K, Ito S. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14: 2255-2263, 2003. (Pubitemid 37052371)
3. Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, Murata T, Salomone S, Shin HK, Ayata C, Moskowitz MA, Michel T, Sessa WC, Huang PL. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest 117: 1961-1967, 2007.
4. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 46: 45-51, 2005. (Pubitemid 40848432)
5. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791 - 1800, 2003.
6. Bobadilla NA, Tapia E, Franco M, Lopez P, Mendoza S, Garcia-Torres R, Alvarado JA, Herrera-Acosta J. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 46: 773-779, 1994. (Pubitemid 24272035)
7. Caron A, Desrosiers RR, Beliveau R. Kidney ischemia-reperfusion regulates expression and distribution of tubulin subunits, beta-actin and rho GTPases in proximal tubules. Arch Biochem Biophys 431: 31-46, 2004. (Pubitemid 39349355)
8. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1: 256-262, 2006.
9. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925-926, 2001. (Pubitemid 34940838)
10. De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92: 1859-1865, 1993.
11. Del Vecchio L, Procaccio M, Vigano S, Cusi D. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 3: 42-49, 2007. (Pubitemid 46020702)
12. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43-52, 2003. (Pubitemid 35463905)
13. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 10: 47-52, 2005.
14. Fujii T, Sugiura T, Ohkita M, Kobuchi S, Takaoka M, Matsumura Y. Selective antagonism of the postsynaptic alpha(1)-adrenoceptor is protective against ischemic acute renal failure in rats. Eur J Pharmacol 574: 185-191, 2007. (Pubitemid 47575520)
15. Goligorsky MS, Brodsky SV, Noiri E. NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology. Semin Nephrol 24: 316-323, 2004. (Pubitemid 38900631)
16. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996. (Pubitemid 26293326)
17. Gros R, Ding Q, Armstrong S, O'neil C, Pickering JG, Feldman RD. Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am J Physiol Cell Physiol 292: C788-C794, 2007.
18. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147: 5363-5373, 2006. (Pubitemid 44790591)
19. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
20. Henry RJ, Segalove M, Sobel C. Turbidimetric determination of proteins with sulfoasalicylic and tricholoroacetic acid. Proc Soc Exp Biol Med 92: 748-751, 1956.
21. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 66: 1-9, 2004. (Pubitemid 38870076)
22. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 14: 2395-2401, 2003. (Pubitemid 37052388)
23. Ishimura T, Fujisawa M, Isotani S, Iijima K, Yoshikawa N, Kamidono S. Endothelial nitric oxide synthase expression in ischemia-reperfusion injury after living related-donor renal transplantation. Transpl Int 15: 635-640, 2002. (Pubitemid 36068179)
24. Jassem W, Heaton ND. The role of mitochondria in ischemia/reperfusion injury in organ transplantation. Kidney Int 66: 514-517, 2004. (Pubitemid 38981989)
25. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 10: 31-37, 2005. (Pubitemid 40895314)
26. Jones DR, Lee HT. Protecting the kidney during critical illness. Curr Opin Anaesthesiol 20: 106-112, 2007.
27. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 286: F1059-F1062, 2004. (Pubitemid 38656360)
28. Just A, Olson AJ, Arendshorst WJ. Dual constrictor and dilator actions of ET(B) receptors in the rat renal microcirculation: interactions with ET(A) receptors. Am J Physiol Renal Physiol 286: F660-F668, 2004. (Pubitemid 38365084)
29. Kelly KJ. Acute renal failure: much more than a kidney disease. Semin Nephrol 26: 105-113, 2006.
30. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 20: 4-19, 2000. (Pubitemid 30048825)
31. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, Mita S, Nakano S, Tsubokou Y, Matsuoka H. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 45: 538-544, 2005. (Pubitemid 40411256)
32. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 37: 1487-1491, 1990. (Pubitemid 20198030)
33. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 365: 417-430, 2005.
34. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 71: 952-958, 1976.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 -Delta Delta C(T) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
36. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
37. Mejia-Vilet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293: F78-F86, 2007. (Pubitemid 47345006)
38. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906-2912, 2005. (Pubitemid 44743488)
39. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 66: 496-499, 2004. (Pubitemid 38981985)
40. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131-F139, 2007. (Pubitemid 46105252)
41. Perez-Rojas JM, Derive S, Blanco JA, Cruz C, Martinez dlM, Gamba G, Bobadilla NA. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 289: F1020-F1030, 2005. (Pubitemid 41447057)
42. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003. (Pubitemid 36384098)
43. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
44. Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, Van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 19: 2086-2097, 2008.
45. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998. (Pubitemid 28124757)
46. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999. (Pubitemid 29065665)
47. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000. (Pubitemid 30815713)
48. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44-49, 2005. (Pubitemid 40187348)
49. Sessa WC. eNOS at a glance. J Cell Sci 117: 2427-2429, 2004.
50. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005. (Pubitemid 41243442)
51. Stanton B, Giebisch G, Klein-Robbenhaar G, Wade J, DeFronzo RA. Effects of adrenalectomy and chronic adrenal corticosteroid replacement on potassium transport in rat kidney. J Clin Invest 75: 1317-1326, 1985. (Pubitemid 15087162)
52. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, Abe Y, Nishiyama A. Involvements of rho-kinase and tgf-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17: 2193-2201, 2006. (Pubitemid 44141909)
53. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 172: 1590-1594, 2004. (Pubitemid 39244992)
54. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, Ramirez V, Glaab WE, Troth SP, Sistare FD, Prozialeck WC, Edwards JR, Bobadilla NA, Mefferd SC, Bonventre JV. A rapid urine test for early detection of kidney injury. Kidney Int 76: 108-114, 2009.
55. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290: F517-F529, 2006. (Pubitemid 43725006)
56. Wagner MC, Rhodes G, Wang E, Pruthi V, Arif E, Saleem MA, Wean SE, Garg P, Verma R, Holzman LB, Gattone V, Molitoris BA, Nihalani D. Ischemic injury to kidney induces glomerular podocyte effacement and dissociation of slit diaphragm proteins Neph1 and ZO-1. J Biol Chem 283: 35579-35589, 2008.
57. Weight SC, Bell PR, Nicholson ML. Renal ischaemia-reperfusion injury. Br J Surg 83: 162-170, 1996.
58. Wellwood JM, Price RG, Ellis BG, Thompson AE. A note on the practical aspects of the assay of N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta 69: 85-91, 1976.
59. Wong S, Brennan FE, Young MJ, Fuller PJ, Cole TJ. A direct effect of aldosterone on endothelin-1 gene expression in vivo. Endocrinology 148: 1511-1517, 2007. (Pubitemid 46457093)
60. Yamasowa H, Shimizu S, Inoue T, Takaoka M, Matsumura Y. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J Pharmacol Exp Ther 312: 153-159, 2005. (Pubitemid 40096464)
61. Yuan J, Zhou J, Chen BC, Zhang X, Zhou HM, Du DF, Chang S, Chen ZK. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc 37: 1892-1895, 2005.